Tamiflu recall

The Committee reported on Tamiflu in January this year, drawing attention to the lack of transparency over the results of clinical trials of the antiviral medicine, stockpiled for use in an influenza epidemic. The Committee concluded that the failure of manufacturers to share the full results of clinical trials with doctors, researchers and clinicians, undermines … Show more

The Committee reported on Tamiflu in January this year, drawing attention to the lack of transparency over the results of clinical trials of the antiviral medicine, stockpiled for use in an influenza epidemic. The Committee concluded that the failure of manufacturers to share the full results of clinical trials with doctors, researchers and clinicians, undermines their ability to make informed decisions about treatments and the use of medicines by the NHS. The Government’s response disagreed with a number of the Committee’s recommendations, including around the availability of full methods and results of clinical trials. This inquiry will examine these issues with the Department, in addition to exploring the Cochrane Collaboration’s updated review of Tamiflu and the ramifications that access to clinical trial data has for the whole of medicine. Further information Public Accounts Committee report: Access to clinical trial information and stockpiling of Tamiflu Government response: Treasury Minutes April 2014 (PDF 715 KB) Show less